Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- PlentisoftWorldFood Moscow 2026: Eurasia's Largest International Food & Drink Exhibition Returns This Autumn With 26,000+ Trade ProfessionalsWorldFood Moscow, Eurasia's leading International Food & Drink Exhibition, has confirmed its return to Crocus Expo, Pavilion 3, Moscow, from 15 to 18 September 2026. Held annually each autumn for more than three decades, WorldFood Moscow is the region's premier international platform connecting food, beverage, and ingredients manufacturers with the buyers, distributors, retailers, and HoReCa professionals driving trade across Russia, the CIS,...
- inFlow InventoryinFlow Inventory launches lot number and expiry date trackingSmall manufacturers and distributors in food, beverage, pharmaceutical and medical device industries can now trace any batch from receipt to customer, at a fraction of the cost of an enterprise — inFlow Inventory has launched lot number and expiry...
- Simply Good Foods Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against The Simply Good Foods Company - SMPLSimply Good Foods (SMPL) Investors Have Opportunity to Lead Simply Good Foods Company Securities Fraud Lawsuit
- UPDATE: Food Basics Invites Ontarians to Nominate Home Cooks to Be Featured in New More Flavours of Home Cookbook SeriesThe series will spotlight community recipes and stories across three editions celebrating Diwali, Lunar New Year and Ramadan.
- Blooms Trade IncBlooms Trade and Silo Technologies Launch Strategic Partnership to Deliver Pre-Approved Capital to the North American Produce Supply ChainBlooms is providing immediate liquidity to the produce supply chain to boost stability, freshness and reduce food waste — Blooms Trade, a financial technology company built to serve the produce industry and boost the North American food...
- oneWeigh from Greenstone Systems Earns “Overall Post Harvest Solution of the Year” in 2026 AgTech Breakthrough Awards ProgramAnnual Awards Program Recognizes Innovation in Agricultural & Food Technologies Around the Globe
- FloVision Winner Of “FoodTech Equipment of the Year” In 2026 AgTech Breakthrough Awards ProgramAnnual Awards Program Recognizes Innovation in Agricultural & Food Technologies Around the Globe
- Jord BioScience Wins “Biological Crop Input Solution of the Year” in 2026 AgTech Breakthrough Awards ProgramAnnual Awards Program Recognizes Innovation in Agricultural & Food Technologies Around the Globe
- Sysco Announces Strategic Board Appointments and AI Transformation Initiatives Intended to Accelerate Growth, Long-Term Value CreationCompanies: SyscoAppoints Two New Directors with Expertise in AI, Innovation, Supply Chain Management, Foodservice Distribution
- Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary FibrosisRein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to LTI-03 for the treatment of idiopathic pulmonary fibrosis.
- Guoquan Reports 22% Revenue Growth in 1H2026, Existing Franchised Stores Sales up 7.4%, Farm GMV Soars Over SixfoldRecently, Guoquan Food (02517) announced its interim results for the six months ended 30 June 2026. The Group recorded revenue of RMB3,947 million, representing an increase of 21.8% year-on-year. Gross profit was RMB849 million, up 18.3% year-on-year, and net profit was RMB213 million, up 12.1% year-on-year. Core operating profit (non-IFRS measure) amounted to RMB225 million, up 18.3% year-on-year, representing a core operating profit margin of 5.7%. Existing Franchised Stores Sales up 7.4%; Large-Store Remodelling Reshapes Per-Store Value When assessing the operational quality of a chain retail enterprise, sales of products to existing franchised stores are a more meaningful metric than new store opening numbers. As of 30 June, the Group had a total of 12,198 stores, representing a net increase of 1,798 stores. During the period, 365 stores were closed, with a store closure rate of below 3%. Revenue from existing franchised stores amounted to RMB2,581 million, representing a year-on-year increase of 7.4%. Excluding the impact of new store ramp-up, this indicates that the existing franchised store network still possesses organic growth momentum. Behind the growth of existing franchised stores, large-store remodelling served as the primary driver. In the first half of the year, 684 stores completed the upgrade to the large-store model. This upgrade is not simply about expanding floor space, but rather about using larger physical space to accommodate a wider range of categories and extended operating hours – expanding consumption scenarios from hotpot and barbecue to cover all daily meal occasions, and upgrading stores from mere ingredient sales points into comprehensive community family dining entry points. Penetration into lower-tier markets progressed simultaneously. The number of stores in township markets reached 3,377. By precisely targeting these markets with high-cost-performance bulk-sale items and large-pack family packs, the “one store per town” strategy taps into the vast hinterland of approximately 38,000 townships nationwide, with penetration potential far from being exhausted. Farm Business Grows Over Sixfold, New Growth Engine Takes Shape Online and membership data also recorded rapid growth. Registered members reached approximately 82 million, representing a year-on-year increase of 63.0%. Member consumption accounted for 73.2% of total sales, up 12 percentage points year-on-year, indicating that the revenue structure is increasingly concentrated among highly loyal customer groups. The Douyin channel saw significant growth: platform exposure exceeded 6.97 billion views, up 117.8% year-on-year; store GMV on Douyin reached RMB910 million, up 97.2%, initially forming a closed loop between online traffic and offline conversion. Guoquan Farm was the fastest-growing business segment during the period. Its omni-channel paid GMV reached RMB240 million, up over 600% year-on-year, and it brought in over 1.92 million new members for the stores. This model does not set up an independent e-commerce platform; instead, it leverages the existing store network as front-end warehouses and pickup points, while online content seeding and traceability livestreams drive traffic, forming a closed loop of “direct sourcing – content seeding – online ordering – in-store pickup”, which theoretically reduces marginal costs. Among best-selling products, the Golden Pillow Durian Pulp attracted a total of 1.559 million buyers, with a repurchase rate of 22.06%, and also boosted sales of related categories such as durian mille-crêpe cakes, Beihai cooked salted duck eggs, and crispy ice cream. In August, the “Grassland Sheep Traceability” livestream achieved over 8.09 million total exposures within three hours, with a peak concurrent viewership of 173,000. The Farm model completely removes the physical constraints of store floor space and freezer capacity from Guoquan’s category boundaries – the “infinite shelf” combined with a 10,000-store fulfilment network represents a critical leap forward in its transformation from a hotpot ingredient retailer to a full-category platform for home dining. Institutionalised Return Mechanisms; Hong Kong Flagship Store Launched The Board proposed the payment of an interim dividend of RMB0.0503 per ordinary share (tax inclusive), totalling approximately RMB128 million. During the period, the Group repurchased a total of 82,201,200 H shares on the Stock Exchange at an aggregate consideration of approximately HK$192 million. The dividend together with the share buybacks amounted to approximately RMB296 million, equivalent to 139.9% of the profit attributable to owners of the parent for the period (RMB211 million). The shareholder return ratio increased from 5.6% in 2024 and 2025 to 7.1%. In addition to the amount, the Board also approved the 2026 H-Share Equity Incentive Plan, which adopts core operating profit as the performance indicator. The reference target values for the years 2026 to 2030 are set to gradually increase from no less than RMB600 million to no less than RMB1.2 billion. By anchoring the assessment to profit rather than revenue or store count, the plan helps guide management to focus on profitability, better aligning management’s interests with those of shareholders. The high dividend payout provides immediate returns, while the equity incentive focuses on long-term growth. The Hong Kong flagship store opened on 18 August, serving as the first stop for the brand’s overseas expansion. Its positioning is not rapid replication, but rather validating the large-store model in high-tier cities and localised supply chain capabilities. According to publicly available data, the Greater Bay Area, with a population of 87 million and an economic aggregate of RMB15 trillion, coupled with the logistics efficiency of the “one-hour living circle”, provides ample room for subsequent regional deepening. Integrated Manufacturing-Retail Closed Loop; Synergies Gradually Unfolding Linking these strategies together is the “manufacturing-retail integration” capability that Guoquan has built over the years. On the front-end “retail” ecosystem – community stores, township stores, large stores, camping stores, stir-fry stores, flash delivery, and Farm – it reaches consumers, understands scenarios, and accumulates member data. On the back-end “manufacturing” ecosystem – seven ingredient production facilities covering core categories such as seasonings, beef, surimi, and aquatic products, with a “single product, single factory” strategy complemented by digitalised central warehouses – it converts front-end demand into scaled product supply. During the period, external sales from the industrial end increased by 20.7% year-on-year, reflecting the potential for the supply chain capability to be externally deployed. The Danzhou Industrial Park in Hainan was topped out, Heyi Meat’s Phase II commenced production, and the Daixiaji Zhangzhou factory was contracted, indicating that the production capacity landscape continues to expand. Looking ahead to the second half of 2026, with the continued replication of the large-store model, the regular operation of the Farm traceability IP, and the gradual accumulation of operating data from the Hong Kong flagship store, Guoquan is expected to gain clearer market recognition of its positioning as a “home dining infrastructure platform”. From a 10,000-store scale to an ecosystem platform, Guoquan’s strategic transformation is entering a substantive realisation phase.
- HELP Therapeutics Announces Nature Medicine Has Published HiCM-188 Clinical Trial Data for Advanced Ischemic Heart FailureAug 19, HELP Therapeutics today announced the Nature Medicine publication of 12-month results from the HEAL-CHF clinical trial evaluating HiCM-188, an investigational allogeneic human iPSC-derived cardiomyocyte (hiPSC-CM) therapy for the treatment of severe ischemic heart failure. The randomized controlled trial enrolled 20 patients, assigned 1:1 to receive either coronary artery bypass grafting (CABG) alone or CABG combined with transepicardial HiCM-188 injection. The study achieved both pre-specified primary safety endpoints, demonstrating no treatment-related tumor formation through 12 months and no sustained ventricular tachycardia through 6 months. At 12 months, 90% of patients receiving transepicardial HiCM-188 injection combined with (CABG improved to NYHA Class II, versus 60% of patients in the CABG-only group.. "HEAL-CHF provides the first clinical evidence that delivering HiCM-188 intraoperatively during CABG may combine the benefits of revascularization with myocardial regeneration," said Professor Dongjin Wang, Lead Author and Director of the Department of Cardiothoracic Surgery at Nanjing Drum Tower Hospital. "Over 12 months, we observed no serious cell-related adverse events alongside encouraging signs of reverse cardiac remodeling. Given the substantial global burden of heart failure and the persistent shortage of donor hearts, regenerative approaches like HiCM-188 have the potential to fill a critical unmet need for patients living with end-stage disease." "The publication of the HEAL-CHF study in Nature Medicine reflects years of dedication to advancing breakthrough stem cell technologies into clinically validated therapies," said Dr. Eugene Jiaxian Wang, Chief Executive Officer of HELP Therapeutics. "With our pivotal Phase III trial now enrolling patients in China and our Phase I program initiating in the U.S., we are eager to maintain this momentum as we work toward bringing a new regenerative medicine breakthrough to heart failure patients worldwide." About HiCM-188 HiCM-188 is an investigational allogeneic human induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) therapy designed as a standardized, off-the-shelf product for scalable manufacturing and distribution. HiCM-188 is the first iPSC-derived cardiomyocyte therapy worldwide to obtain Investigational New Drug (IND) clearances from both the U.S. FDA and China's NMPA. It is currently being evaluated in a multicenter Phase III trial in China led by TEDA International Cardiovascular Hospital, and a Phase I trial in the United States at the Texas Heart Institute. About HELP Therapeutics Founded in 2016, HELP Therapeutics is a global clinical-stage biopharmaceutical company developing iPSC-based cell therapies for cardiovascular and other degenerative diseases. The company leverages proprietary off-the-shelf cell therapy platforms and national iPSC bank infrastructure to ensure scalable clinical and commercial delivery. HELP Therapeutics has established a commercialization partnership with China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (SZSE: 000999) to build out distribution infrastructure in China. For more information, please visit https://en.helptherapeutics.com. Disclosure Notice The information contained in this release is as of August 19, 2026. HiCM-188 is an investigational product and has not been approved for commercial use by the U.S. Food and Drug Administration, China National Medical Products Administration, or any other regulatory authority. This release contains forward-looking statements regarding HiCM-188, including potential clinical benefits and regulatory development timelines, which involve substantial risks and uncertainties that could cause actual results to differ materially. References & Publication Details 1.Journal: Nature Medicine (2026) DOI: 0.1038/s41591-026-04605-1 2.Clinical Trial Registry: ClinicalTrials.gov (NCT03763136) 3.Ethics Approval: Nanjing Drum Tower Hospital IRB (No. SC202000102); National Health Commission of China (MR-32-21-014649)